

MHealth/UMMC Summary of Anticoagulation Reversal

Drug	Drug class	Elimination half-life	Summary of emergent reversal for life threatening bleeding or need for emergent surgery								
Apixaban (Eliquis)	Direct FXa inhibitor	12h (longer with renal impairment)	<ul style="list-style-type: none"> -If ingested within 2 hours, consider giving activated charcoal 1g/kg (max 50g) -Administer Kcentra (4-factor PCC) 50units/kg x1 (max 5000units) -If Kcentra ineffective, consult hematology and consider recombinant activated factor VII (Novoseven) 90 mcg/kg IV once, max 10 mg -Drug activity can be assessed with anti-factor Xa assay. However, this may not accurately reflect the degree of anticoagulation -If anti-factor Xa level is <0.1 IU/mL, consider other causes for bleeding -Reversal agent adexanet alpha not yet available 								
Argatroban	Direct thrombin inhibitor	40-50 min (longer in pts with hepatic dysfunction)	<ul style="list-style-type: none"> -Turn off infusion -Degree of reversal can be assessed with PTT -Consider KCentra (4-factor PCC) 50units/kg x 1 (max 5000units)for life threatening bleeding 								
Betrixaban (Bevyssa)	Direct FXa inhibitor	20-27h	<ul style="list-style-type: none"> -Administer 4-factor PCC(Kcentra) 50u/kg x 1 (max 5000u) -If Kcentra ineffective, consult hematology and consider recombinant Novoseven (activated factor VII) 90 mcg/kg IV once, max 10 mg -If anti-factor Xa level is <0.1 IU/mL, consider other causes for bleeding 								
Bivalrudin	Direct thrombin inhibitor	25 min (longer in pts with renal impairment)	<ul style="list-style-type: none"> -Turn off infusion -Degree of reversal can be assessed with PTT -Consider Kcentra (4 factor PCC) 50units/kg x 1 (max 5000units) for life threatening bleeding 								
Dabigatran (Pradaxa)	Direct thrombin inhibitor	14h (up to 34h in severe renal impairment)	<ul style="list-style-type: none"> -If ingested within 2 hours, consider giving activated charcoal 1g/kg (max 50g) -Administer idarucizumab (Praxbind)5 mg IV once (given as 2 consecutive IV infusions of 2.5 g vials over 5 min each. The 2nd vial must be given within 15 min of the first). -If Praxbind ineffective, consider recombinant activated factor VII (Novoseven) 90 mcg/kg IV once, max 10 mg -Plasma transfusion not expected to reverse effects 								
Dalteparin (Fragmin)	LMWH	3-5h (longer with renal impairment)	<ul style="list-style-type: none"> -Use protamine for partial neutralization (~60%) <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; color: #c00000;">Time since last dose of LMWH</th> <th style="text-align: left; color: #c00000;">Dose of protamine for each 100u of dalteparin or 1 mg of enoxaparin given</th> </tr> </thead> <tbody> <tr> <td style="color: #c00000;"><8 hours</td> <td style="color: #c00000;">1mg (or 50 mg fixed dose)</td> </tr> <tr> <td style="color: #c00000;">8-12 hours</td> <td style="color: #c00000;">0.5mg (or 25 mg fixed dose)</td> </tr> <tr> <td style="color: #c00000;">>12 hours</td> <td style="color: #c00000;">Not likely to be useful (or 25mg fixed dose)</td> </tr> </tbody> </table> <ul style="list-style-type: none"> -Monitor anti-factor Xa activity level to confirm reversal -For refractory or life threatening bleeding, administer Kcentra (4 factor PCC) 50u/kg x 1 (max dose 5000u) 	Time since last dose of LMWH	Dose of protamine for each 100u of dalteparin or 1 mg of enoxaparin given	<8 hours	1mg (or 50 mg fixed dose)	8-12 hours	0.5mg (or 25 mg fixed dose)	>12 hours	Not likely to be useful (or 25mg fixed dose)
Time since last dose of LMWH				Dose of protamine for each 100u of dalteparin or 1 mg of enoxaparin given							
<8 hours	1mg (or 50 mg fixed dose)										
8-12 hours	0.5mg (or 25 mg fixed dose)										
>12 hours	Not likely to be useful (or 25mg fixed dose)										
Enoxaparin (Lovenox)											
Edoxaban (Savaysa)	Direct FXa inhibitor	10-14h (longer with renal impairment)	<ul style="list-style-type: none"> -If ingested within 2 hours, consider giving activated charcoal 1g/kg (max 50g) -Administer 4 factor PCC (Kcentra) 50units/kg x1 (max 5000units) -If Kcentra ineffective, consult hematology and consider recombinant activated factor VII (Novoseven) 90 mcg/kg IV once, max 10 mg -Drug activity can be assessed with anti-factor Xa assay. However, this may not accurately reflect the degree of anticoagulation -If anti-factor Xa level is <0.1 IU/mL, consider other causes for bleeding 								
Fondaparinux (Arixtra)	Antithrombin mediated inhibition of FXa	17-21h (++) longer with renal impairment)	<ul style="list-style-type: none"> -Administer Kcentra (4 factor PCC) 50u/kg x 1 (max 5000u) -Monitor aPTT/ anti factor Xa levels 								
Heparin	AT III enhancer	30-90 min	<ul style="list-style-type: none"> -Administer protamine: <ul style="list-style-type: none"> For each 1000 units of heparin, administer 1mg of protamine -Do not exceed rate of 5 mg/min, max dose is 50 mg 								

Rivaroxaban (Xarelto)	Direct FXa inhibitor	5-9h Elderly: 11-13h (longer with renal impairment)	-If ingested within 2 hours, consider giving activated charcoal 1g/kg (max 50g) -Administer Kcentra (4-factor PCC) 50units/kg x1 (max 5000units) -If Kcentra ineffective, consult hematology and consider recombinant activated factor VII (Novoseven) 90 mcg/kg IV once, max 10 mg -Drug activity can be assessed with anti-factor Xa assay. However, this may not accurately reflect the degree of anticoagulation -If anti-factor Xa level is <0.1 IU/mL, consider other causes for bleeding -Reversal agent adexanet alpha not yet available	
Warfarin (Coumadin)	Vit K antagonist	Clinical Scenario	INR	Management
		No bleeding	<4.5	Hold Warfarin or lower dose and check daily INR
			4.5 – 9.9	Preferred treatment <ul style="list-style-type: none"> • Omit next 1-2 doses. Resume at adjusted dose once INR therapeutic • If INR remains the same or increases despite holding ≥ 3 doses, consider giving vit K <ul style="list-style-type: none"> ○ High risk thrombosis patients- avoid vit K if possible; If needed give 1-2 mg PO x 1 ○ All other patients- 2.5 – 5 mg PO x 1 • INR daily
			>10	Hold Warfarin AND give vit K at the following doses <ul style="list-style-type: none"> ○ High risk thrombosis patients- avoid vit K if possible; If needed give 1-2 mg PO x 1 ○ All other patients- 2.5 – 5 mg PO x 1 • INR daily • For patients at very high risk for bleeding consider FFP/ Kcentra
	Mild to moderate bleeding OR surgical procedure <24h	1.8 – 4.5 Hold Warfarin, daily INR, 2 mg IV vit K once 4.5 – 9.9 Hold Warfarin, daily INR, 5 mg IV vit K once >10 Hold Warfarin, daily INR, 10 mg IV vit K once If patient continues to bleed despite Vit K or INR remains elevated above acceptable level, consider <ul style="list-style-type: none"> • FFP transfusion • Kcentra 25U/kg IV once max 2500 units. Recheck INR 30 min after Kcentra 		
	Major life threatening bleed OR requiring emergent procedure	Any > 1.4 <ul style="list-style-type: none"> • Hold warfarin AND • Vitamin K 10 mg IV once (over 30 minutes) AND • Kcentra (4 factor PCC) <ul style="list-style-type: none"> ○ INR <2: 25 units/kg IV once (max 2500 units) ○ INR 2- 3.9: 25 units/kg IV once (max 2500 units) ○ INR 4-6: 35 units/kg IV once (max 3500 units) ○ INR >6: 50 units/kg IV once (max 5000 units) <p>Recheck INR 30 minutes after Kcentra, then q6h x 24h</p> <ul style="list-style-type: none"> • If INR > 2.0 and/or bleeding heavily AFTER Kcentra, consider <ul style="list-style-type: none"> ○ TEG ○ Hematology consult ○ 4-6 units FFP ○ Pro-hemostatic agents ○ If all above not effective, consider recombinant factor VII (Novoseven) 20 mcg/kg once 		